Bausch + Lomb files IPO registration with SEC
ROCHESTER, N.Y. — Bausch + Lomb on Friday announced that it has filed a registration statement with the U.S. Securities and Exchange Commission to take the company public. The number of shares to be offered and the price range for the proposed offering have not yet been determined, the company stated.
The proposed IPO could raise as much as $1.5 billion and is expected to value Bausch & Lomb at about $9 billion to $10 billion, Reuters reported earlier in March.
Get connected and follow us on LinkedIn for the most in-depth coverage of drug store news. Join the conversation.
SoloHealth fills new role of director of business planning and analytics
ATLANTA — SoloHealth on Friday named Joe Stephens to the newly created role of director of business planning and analytics. Stephens will focus on organizing business development initiatives, priorities, metrics and efficiencies, as well as helping guide new-business exploration as the company continues its growth.
Stephens will report directly to Stephen Kendig, chief commercial officer and EVP of SoloHealth, effective immediately.
“Joe brings a fresh and unique perspective and expertise to the SoloHealth team as we continue to rapidly scale our platform nationally and explore other strategic opportunities within the health services space,” Kendig said. “His background in sales and analytics, along with his start-up mentality, makes him a strong fit for SoloHealth.”
Prior to SoloHealth, Stephens served as the VP of business process improvement at Transcend Services for a year prior to the acquisition by Nuance Communication in April 2012. Stephens began his career as a sales engineer with Carrier Corporation in Mobile, Alabama, where he worked alongside engineers and commercial contractors in the design and layout of HVAC systems for commercial applications.
Stephens holds undergraduate degrees in electrical engineering and finance from Auburn University and an MBA focused in finance and strategic marketing from Indiana University.
LifeScan recalls OneTouch VerioIQ blood-glucose meters
MILPITAS, Calif. — LifeScan on Monday initiated a voluntary recall and replacement for all of its OneTouch VerioIQ blood-glucose meters in the United States, effective immediately.
“Our patients’ safety is our number one priority,” stated Michael Pfeifer, LifeScan’s chief medical officer. “When we learn that a product does not fully meet our expected standards, we will voluntarily notify our customers and patients and take corrective action. We regret the inconvenience these actions may cause. However, we will always err on the side of caution and make a decision that is in the best interest of our patients.”
LifeScan is recalling and replacing the meters because at extremely high blood glucose levels of 1024 mg/dL and above, the meter will not provide a warning that the blood glucose is extremely high and will shut off, thereby potentially leading to incorrect treatment and delaying proper treatment.
The likelihood of experiencing an extremely high blood glucose level of 1024 mg/dL or higher is remote; however, when such a blood glucose level occurs, it is a serious health risk requiring immediate medical attention. Because these products do not provide an appropriate warning at glucose levels of 1024 mg/dL or higher, diagnosis and treatment of extreme hyperglycemia may be delayed.
Patients who are using the OneTouch VerioIQ Meter should contact LifeScan Customer Service at (800) 717-0276 to make arrangements to receive a replacement meter at no charge and to speak with a LifeScan representative. Representatives are available 8 a.m. to 10 p.m. EDT Monday through Sunday. Additional information about this recall is available on www.onetouch.com.
Patients may continue to test with their OneTouch VerioIQ Meters while they wait for their replacement meter to arrive as long as they are aware of this issue, Lifescan stated. However, LifeScan advises that if the meter unexpectedly turns itself off during testing, this could be a sign of extreme hyperglycemia requiring immediate medical attention and the patient should call a healthcare professional.
Notifications are being sent to all registered users, healthcare professionals, pharmacies and distributors wherever these products are sold. LifeScan estimates that there are approximately 90,000 active OneTouch VerioIQ Meter users in the U.S. The company is in the process of implementing an update to the meter to address the issue, however, the timing to resume shipments of OneTouch VerioIQ Meters has not yet been determined.
To date, no adverse events or patient injuries related to this specific issue have been reported for the OneTouch VerioIQ Meter. All other OneTouch blood glucose brands sold in the U.S., including OneTouch Ultra Meters, OneTouch Select Meters and OneTouch Verio Test Strips, are not affected by this recall.
Like this story? Find us on Facebook for more insight, analysis and the latest in drug store news. Join the conversation.